Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS Gains 9%; BSE HEALTHCARE Index Up 0.7%
Wed, 21 Aug 10:7

SYNCOM FORMULATIONS Gains 9%; BSE HEALTHCARE Index Up 0.7%Image source: DNY59/www.istockphoto.com

SYNCOM FORMULATIONS share price has zoomed 9% and is presently trading at Rs 17.7.

Meanwhile, the BSE HEALTHCARE index is at 41,920.4 (up 0.7%).

Among the top gainers in the BSE HEALTHCARE index today are Divis Laboratories (up 3.2%) and ALEMBIC PHARMA (up 3.1%).

Aurobindo Pharma (down 1.2%) and MAX HEALTHCARE INSTITUTE (down 0.5%) are among the top losers today.

Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 8.4 to Rs 17.7, registering a gain of Rs 9.3 (up 110.7%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,021.8 to 41,920.4, registering a gain of 49.6% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 128.3%), Glenmark Pharma (up 114.1%) and GSK Pharma (up 110.6%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 80,708.4 (down 0.1%).

The top losers among the BSE Sensex today are Ultratech Cement (down 1.9%) and ICICI Bank (down 0.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 24,697.8 . Ultratech Cement and ICICI Bank are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,216.1 to 80,708.4, registering a gain of 15,492.3 points (up 23.8%).

SYNCOM FORMULATIONS Financial Update...

SYNCOM FORMULATIONS net profit grew 73.6% YoY to Rs 76 million for the quarter ended June 2024, compared to a profit of Rs 44 million a year ago. Net sales rose 45.8% to Rs 873 million during the period as against Rs 598 million in April-June 2023.

For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.

The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 58.2.


Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 9%; BSE HEALTHCARE Index Up 0.7%". Click here!